Logo image of BEAM

BEAM THERAPEUTICS INC (BEAM) Stock Fundamental Analysis

NASDAQ:BEAM - Nasdaq - US07373V1052 - Common Stock - Currency: USD

20.24  +0.41 (+2.07%)

After market: 20.31 +0.07 (+0.35%)

Fundamental Rating

3

Overall BEAM gets a fundamental rating of 3 out of 10. We evaluated BEAM against 563 industry peers in the Biotechnology industry. While BEAM seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, BEAM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BEAM has reported negative net income.
In the past year BEAM has reported a negative cash flow from operations.
In the past 5 years BEAM always reported negative net income.
BEAM had negative operating cash flow in 4 of the past 5 years.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.13%, BEAM is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
BEAM has a Return On Equity of -51.36%. This is in the better half of the industry: BEAM outperforms 64.20% of its industry peers.
Industry RankSector Rank
ROA -34.13%
ROE -51.36%
ROIC N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

BEAM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K

More info and screens

6

2. Health

2.1 Basic Checks

BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
BEAM has more shares outstanding than it did 1 year ago.
BEAM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of 0.88, we must say that BEAM is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.88, BEAM is doing good in the industry, outperforming 66.84% of the companies in the same industry.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACC10.09%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

BEAM has a Current Ratio of 4.82. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.82, BEAM perfoms like the industry average, outperforming 54.32% of the companies in the same industry.
BEAM has a Quick Ratio of 4.82. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
BEAM has a Quick ratio (4.82) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.82
Quick Ratio 4.82
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

BEAM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -141.05%.
BEAM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -83.18%.
The Revenue has been growing by 401.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-141.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.01%
Revenue 1Y (TTM)-83.18%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-90.49%

3.2 Future

BEAM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.12% yearly.
Based on estimates for the next years, BEAM will show a very strong growth in Revenue. The Revenue will grow by 60.40% on average per year.
EPS Next Y-6.98%
EPS Next 2Y-3.78%
EPS Next 3Y-2.57%
EPS Next 5Y10.12%
Revenue Next Year16.24%
Revenue Next 2Y11.17%
Revenue Next 3Y13.03%
Revenue Next 5Y60.4%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BEAM. In the last year negative earnings were reported.
Also next year BEAM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A cheap valuation may be justified as BEAM's earnings are expected to decrease with -2.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.78%
EPS Next 3Y-2.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BEAM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAM THERAPEUTICS INC

NASDAQ:BEAM (5/2/2025, 8:00:01 PM)

After market: 20.31 +0.07 (+0.35%)

20.24

+0.41 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners95.33%
Inst Owner Change1.01%
Ins Owners1.42%
Ins Owner Change8.47%
Market Cap2.04B
Analysts84.35
Price Target50.49 (149.46%)
Short Float %18.98%
Short Ratio7.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.01%
Min EPS beat(2)0.76%
Max EPS beat(2)11.25%
EPS beat(4)4
Avg EPS beat(4)7.96%
Min EPS beat(4)0.76%
Max EPS beat(4)16.31%
EPS beat(8)8
Avg EPS beat(8)42.53%
EPS beat(12)11
Avg EPS beat(12)34.68%
EPS beat(16)13
Avg EPS beat(16)2.48%
Revenue beat(2)1
Avg Revenue beat(2)35.3%
Min Revenue beat(2)-3.52%
Max Revenue beat(2)74.11%
Revenue beat(4)1
Avg Revenue beat(4)-1.3%
Min Revenue beat(4)-57.18%
Max Revenue beat(4)74.11%
Revenue beat(8)4
Avg Revenue beat(8)203.91%
Revenue beat(12)8
Avg Revenue beat(12)161.39%
Revenue beat(16)11
Avg Revenue beat(16)298.41%
PT rev (1m)0.73%
PT rev (3m)3.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.04
P/FCF N/A
P/OCF N/A
P/B 2.77
P/tB 2.77
EV/EBITDA N/A
EPS(TTM)-4.58
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.45
OCFYN/A
SpS0.63
BVpS7.29
TBVpS7.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.13%
ROE -51.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.8%
Cap/Sales 14.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.82
Quick Ratio 4.82
Altman-Z 0.88
F-Score2
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)185.1%
Cap/Depr(5y)305.75%
Cap/Sales(3y)34.46%
Cap/Sales(5y)16398.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-141.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.01%
EPS Next Y-6.98%
EPS Next 2Y-3.78%
EPS Next 3Y-2.57%
EPS Next 5Y10.12%
Revenue 1Y (TTM)-83.18%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-90.49%
Revenue Next Year16.24%
Revenue Next 2Y11.17%
Revenue Next 3Y13.03%
Revenue Next 5Y60.4%
EBIT growth 1Y-135.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.98%
EBIT Next 3Y-8.22%
EBIT Next 5Y8.74%
FCF growth 1Y-94.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-132.75%
OCF growth 3YN/A
OCF growth 5YN/A